BeiGene’s Tislelizumab Receives 11th NMPA Filing for First-Line Esophageal Cancer
BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) announced that the National Medical Products Administration (NMPA)...
Innovent Biologics Doses First Patient in Australia Trial for PD-1/IL-2 Bispecific Antibody IBI363
China-based Innovent Biologics, Inc. (HKG: 1801) announced that the first patient has been dosed in...
Lee’s Pharma Expands Global Rights to Windtree’s KL4 Surfactant Products
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has expanded its licensing agreement with US-based Windtree...
Genetron Holdings Receives Buyout Offer from CEO Wang Sizhen at USD 1.36 per ADS
Beijing-based precision oncology firm Genetron Holdings Ltd announced receipt of a buyout and take-private offer...
Supreme People’s Court Rules Against Chugai in China’s First Patent Linkage Case
China’s Supreme People’s Court has delivered its verdict in the nation’s first patent linkage dispute,...
Ascletis Pharma’s H1 2022 Revenue Rises 4.8% on R&D and Product Sales Growth
Ascletis Pharma Inc. (HKG: 1672) reported RMB 38.2 million (USD 5.96 million) in revenue for...
Viatris Pharmaceuticals’ HIV/AIDS Drug Prioritized for CDE Review
The Center for Drug Evaluation (CDE) has indicated that Viatris Pharmaceuticals Co., Ltd’s efavirenz/lamivudine/tenofovir is...
Hansoh Pharma Licenses GHDDI’s GDI-4405 for Global Development in COVID-19
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced a licensing agreement with the Global...
Anhui Anke’s HK010 Bispecific Antibody Receives NMPA Review for Cancer Trials
Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) announced that the National Medical Products Administration...
China-Based Firms Form Partnership to Advance Cell and Gene Therapy Ecosystem
Six China-based companies—Porton Advanced Solutions Ltd, Shanghai Sequanta Biological Technology Co., Ltd, QuaCell Biotechnology Co.,...
BIOPSEE Series A+ Financing Confocal Microendoscope
BIOPSEE, a Hubei-based microendoscope specialist, has raised tens of millions of renminbi in a Series...
CSPC Pharmaceutical’s DBPR108 Hits Endpoints in Type 2 Diabetes Trials
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its Category 1 drug DBPR108 has...
Shanghai Pharmaceuticals Gets NMPA Approval for B013 in Triple-Negative Breast Cancer
Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) has received approval from the National Medical Products Administration...
Scitop Bio-tech’s KEX02 Live Bacteria Therapy Gets FDA IND Approval for NSCLC
Beijing Scitop Bio-tech Co., Ltd (SHE: 300858) announced that the US Food and Drug Administration...
Sanyou Biopharmaceuticals and KangaBio Ink Licensing Deal for Antibody Drug Candidate
Shanghai-based Sanyou Biopharmaceuticals Co., Ltd and KangaBio have entered into a licensing agreement, granting Kanga...
InnoCare Pharma’s 2022 Interim Report Shows Strong Revenue Growth Driven by Orelabrutinib Sales
China-based InnoCare Pharma (HKG: 9969) announced its 2022 interim financial results, reporting total revenues of...
Porton Biologics Completes RMB 520M Series B to Expand Gene and Cell Therapy CDMO Platform
Suzhou Porton Biologics Ltd, a China-based contract development and manufacturing organization (CDMO), announced the completion...
Nuance Pharma Gets NMPA Green Light for Ensifentrine COPD Trials in China
China-based Nuance Pharma has secured approval from the National Medical Products Administration (NMPA) to conduct...
Lundbeck’s Vyepti Fails to Accelerate China Launch via SUNLIGHT Trial
Lundbeck’s attempt to fast-track migraine drug Vyepti (eptinezumab) into China and Asia via the SUNLIGHT...
Mindray Bio-Medical’s H1 2022 Revenues Jump 20.17% to RMB 15.3B
Shenzhen Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760) reported robust financial results for H1 2022,...